Akanda

Akanda Operating Expenses

The Total Operating Expenses of Akanda (AKAN) as of Oct 26, 2026 is 4.39 M USD. In the previous year, Total Operating Expenses was 4.45 M USD — a change of -1.26% (lower).

Operating Expenses

4.39 MUSD

YoY

-1.26%

Last updated:

Total Operating Expenses of Akanda is 2025 4.39 M USD. Total Operating Expenses of Akanda was 2024 4.45 M USD. It decreases by -1.26% lower compared to the previous year.

The Akanda Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
702,411.00 USD
Jan 1, 2020
1.36 M USD
Jan 1, 2021
5.81 M USD
Jan 1, 2022
19.85 M USD
Jan 1, 2023
5.88 M USD
Jan 1, 2024
4.45 M USD
Jan 1, 2025
4.39 M USD
The Akanda Operating Expenses history
YEAROperating ExpensesYoY
4.39 MUSD-1.26%
4.45 MUSD-24.31%
5.88 MUSD-70.38%
19.85 MUSD+241.61%
5.81 MUSD+327.59%
1.36 MUSD+93.45%
702,411.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Total Operating Expenses of Akanda is 4.39 M USD in 2025.

Total Operating Expenses of Akanda changed from 4.45 M USD to 4.39 M USD, representing a -1.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Akanda since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Akanda historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Akanda

All Key Metrics — Akanda